Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

807.85INR
19 Dec 2014
Price Change (% chg)

Rs-4.15 (-0.51%)
Prev Close
Rs812.00
Open
Rs816.20
Day's High
Rs820.00
Day's Low
Rs804.30
Volume
1,835,976
Avg. Vol
2,484,695
52-wk High
Rs932.50
52-wk Low
Rs552.55

SUN.NS

Chart for SUN.NS

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.61
Market Cap (Mil.): Rs1,673,190.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.19

Financials

  SUN.NS Industry Sector
P/E (TTM): 27.79 37.83 38.47
EPS (TTM): 29.07 -- --
ROI: 32.12 18.99 18.25
ROE: 31.49 19.75 19.13
Search Stocks

Indian FX/debt factors to watch - Dec 9

GLOBAL MARKETS ROUNDUP * Asian share markets were mostly in the red on Tuesday while the U.S. dollar began to edge higher once again aided by a media report the Federal Reserve might take a rhetorical step toward tightening at its meeting next week. * The yen held onto sizeable gains early on Tuesday, having staged a broad short-covering rally as a big drop in oil prices hit global risk appetite. Both the dollar and euro fell from multi-year peaks with the greenback sliding to 120.

09 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)

09 Dec 2014

CORRECTED-Deals of the day- Mergers and acquisitions

(Removes erroneous reference to Canadian Solar in Sharp Corp item)

09 Dec 2014

Antitrust regulator CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories , but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

MUMBAI - Sun Pharmaceutical Industries, India's largest drugmaker by revenue, on Thursday posted a 15 percent rise in quarterly net profit, roughly in line with expectations, helped by strong growth in sales in the domestic market.

13 Nov 2014

Ranbaxy books first profit in six quarters on exclusive drug launch

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd on Tuesday reported its first profit in six quarters after benefiting from the exclusive U.S. launch of a cheaper copy of Novartis AG blood pressure pill Diovan.

28 Oct 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

Ranbaxy surges after profit, Sun Pharma also gains

Reuters Market Eye - Ranbaxy Laboratories gains 4.5 percent. Sun Pharmaceutical Industries , which is in the process of acquiring Ranbaxy, also jumps 4.4 percent.

28 Oct 2014

MARKET EYE -India's Ranbaxy surges after profit, Sun Pharma also gains

* Ranbaxy Laboratories gains 4.5 percent. * Sun Pharmaceutical Industries, which is in the process of acquiring Ranbaxy, also jumps 4.4 percent. * Ranbaxy posts a profit of 4.78 billion rupees ($78 million), compared with a loss of 4.5 billion rupees a year earlier. * The company's earnings got a boost from the launch of generic Valsartan in the U.S. with 180 days exclusivity - Analysts. * Valsartan is a cheaper copy of Novartis AG's blood pressure pill Diovan. * The Indian pharma index gaine

28 Oct 2014

Sun Pharma gains on cash position, receding USFDA risk

Reuters Market Eye - Sun Pharmaceutical Industries gains 3.3 percent.

29 Sep 2014

Earnings vs. Estimates

Search Stocks